CDH6: A Potential Drug Target and Biomarker (G1004)

Target Name: CDH6

NCBI ID: G1004

CDH6: A Potential Drug Target and Biomarker

CDH6 (chromodomain and histone-containing protein 6) is a protein that plays a crucial role in the development and maintenance of tissues, including blood cells, neural cells, and epithelial cells. CDH6 has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

CDH6 Structure and Function

CDH6 is a 21-kDa protein that consists of 215 amino acid residues. It has a characteristic domains that include a long N-terminal domain, a short C-terminal domain, and a middle prolylated lysine (PML) domain. The PML domain is a unique feature that is found in a variety of proteins and plays a critical role in the regulation of chromatin structure and gene expression.

CDH6 functions as a chromatin-remodeling enzyme. It can add a PML domain to the ends of repressed genes and enhance their accessibility to transcription factors, thereby promoting gene expression. CDH6 has been shown to play a role in the regulation of stem cell maintenance, proliferation, and differentiation.

CDH6 as a Potential Drug Target

CDH6 has been identified as a potential drug target due to its involvement in several diseases. The ability of CDH6 to regulate gene expression and contribute to the maintenance of tissues makes it an attractive target for small molecules. Several studies have shown that inhibiting CDH6 activity can lead to therapeutic effects in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising CDH6-targeted drugs is a small molecule inhibitor called CS-901253. This compound inhibits CDH6 activity and has been shown to have therapeutic effects in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

CDH6 as a Biomarker

CDH6 has also been identified as a potential biomarker for several diseases. The ability of CDH6 to regulate gene expression makes it an attractive target for the development of diagnostic tools. Several studies have shown that the expression of CDH6 is altered in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising biomarker studies is a study of CDH6 expression in neurodegenerative diseases. Researchers have shown that CDH6 expression is increased in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that CDH6 may be a useful biomarker for these diseases and could be targeted by small molecules to improve treatment outcomes.

Conclusion

CDH6 is a protein that plays a critical role in the development and maintenance of tissues and has been identified as a potential drug target and biomarker for several diseases. The unique PML domain of CDH6 and its involvement in chromatin-remodeling provide a promising framework for the development of new therapeutic compounds. Further research is needed to fully understand the role of CDH6 in disease and to develop effective treatments.

Protein Name: Cadherin 6

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types

More Common Targets